Condensed Consolidated Balance Sheets (U.S. Dollars in thousands)

	December 31, 2011	June 30, 2012
Current assets		(Unaudited)
Cash and cash equivalents	17,386	12,044
Available-for-sale marketable securities	10,334	5,671
Short-term bank deposits	88,773	118,041
Trade receivables, net	12,565	17,733
Other receivables and prepaid expenses	3,625	3,332
Inventories	12,147	12,493
	144,830	169,314
Long-term investments		
Available-for-sale marketable securities	102,644	114,479
Severance pay funds	3,047	2,823
	105,691	117,302
Property and equipment, net	11,084	10,663
Other assets		
Intangible assets, net	8,163	6,645
Other long-term assets	1,365	1,143
Goodwill	24,465	24,465
	24,400	24,400
Total assets	295,598	329,532
Current liabilities		
Trade payables	5,099	4,798
Deferred revenues, other payables and	5,099	4,790
accrued expenses	43,732	56,899
accided expenses	48,831	61,697
	40,031	01,097
Long-term liabilities	27,446	20,675
Charabaldara' a with		
Shareholders' equity	538	F 40
Share capital Additional paid-in capital	528 233,353	546 244,559
Accumulated other comprehensive	233,303	244,559
income (loss)	(1,663)	528
Treasury stock, at cost	(18,036)	(18,036)
Retained earnings	5,139	19,563
Total shareholders' equity	219,321	247,160
	213,321	247,100
Total liabilities and shareholders' equity	295,598	329,532
······································		

Condensed Consolidated Statements of Income (U.S. Dollars in thousands, except share and per share data)

	For the Three months ended June 30,		For the Six months ended June 30,	
	<u>2011</u> (Unaudited)	2012 (Unaudited)	<u>2011</u> (Unaudited)	<u>2012</u> (Unaudited)
Revenues Cost of revenues Gross profit Operating expenses: Research and development Selling and marketing General and administrative Total operating expenses Operating income Financial income, net Income before taxes on income Taxes on income Net Income	41,115 <u>8,318</u> <u>32,797</u> 9,092 17,339 <u>2,436</u> <u>28,867</u> 3,930 <u>1,298</u> 5,228 <u>(298)</u> <u>4,930</u>	46,802 <u>8,810</u> <u>37,992</u> 8,943 19,017 <u>2,427</u> <u>30,387</u> 7,605 <u>989</u> 8,594 (1,043) <u>7,551</u>	79,734 <u>16,197</u> <u>63,537</u> 17,796 33,745 <u>4,785</u> <u>56,326</u> 7,211 <u>2,637</u> 9,848 <u>(529)</u> 9,319	91,823 <u>17,342</u> <u>74,481</u> 18,095 37,704 <u>4,831</u> <u>60,630</u> 13,851 <u>2,491</u> 16,342 (<u>1,918</u>) <u>14,424</u>
Basic net earnings per share	<u>\$ 0.24</u>	<u>\$ 0.35</u>	<u>\$ 0.45</u>	<u>\$ 0.67</u>
Weighted average number of shares used to compute basic net earnings per share	20,927,549	21,859,625	20,801,998	21,677,698
Diluted net earnings per share Weighted average number of shares used to compute diluted net earnings per share	<u>\$ 0.21</u> 22,976,000	<u>\$ 0.32</u> 23,399,494	<u>\$ 0.41</u> 23,001,985	<u>\$ 0.62</u> 23,268,450

Reconciliation of Supplemental Financial Information (U.S. Dollars in thousands, except share and per share data)

	For the Three months ended June 30,		For the Six months ended June 30,	
	<u>2011</u> (Unaudited)	<u>2012</u> (Unaudited)	<u>2011</u> (Unaudited)	<u>2012</u> (Unaudited)
GAAP net Income Stock-based compensation expenses, included in:	<u>4,930</u>	<u>7,551</u>	<u>9,319</u>	<u>14,424</u>
Cost of revenues	16	17	31	38
Research and development	286	279	539	607
Selling and marketing	781	860	1,391	1,826
General and administrative	345	254	663	528
	1,428	<u>1,410</u>	2,624	2,999
Amortization of intangible assets included in:				
Cost of revenues	541	467	1,082	935
Selling and marketing	421	292	842	583
	962	759	1,924	<u>1,518</u>
Exchange rate differences, net on balance sheet items included in finance expenses	(07)	207	(400)	40
(income)	<u>(67)</u>	287	(496)	<u> 19</u>
Non-GAAP net income	_7,253	<u>10,007</u>	<u>13,371</u>	<u>18,960</u>
Non-GAAP diluted net earnings per share	<u>\$ 0.32</u>	<u>\$ 0.43</u>	<u>\$ 0.58</u>	<u>\$ 0.81</u>
Weighted average number of shares used to compute Non-GAAP diluted net earnings per share	22,976,000	23,399,494	23,001,985	23,268,450